AZAFAROS-B.V.
Azafaros B.V. today announced positive topline data from its RAINBOW study, a Phase 2 clinical trial investigating nizubaglustat in patients with a genetic diagnosis of either GM2 gangliosidosis or Niemann-Pick disease type C (NPC).
About the Trial
The trial was conducted across three sites in Brazil, involving 13 patients older than 12 years of age, with the aim of determining the safety, pharmacodynamics, and pharmacokinetics of two different doses of nizubaglustat. The results will guide the identification of the target dose for Azafaros’ planned Phase 3 pivotal studies.
With the 12-week, double-blind and placebo-controlled part of the study complete, patients have now entered the extension phase, where all participants receive the study drug.
The data from the RAINBOW study will be presented at the SSIEM Annual Symposium 2024, which will take place on 3 - 6 September in Porto, Portugal.
Stefano Portolano, CEO at Azafaros, said: “The results of the Phase 2 RAINBOW study mark a pivotal moment in the development of nizubaglustat. The dual mode of action sets nizubaglustat apart as a leap forward from other agents. We are excited by the results of the study and more than confident that nizubaglustat has the potential to become a convenient, life-changing therapy for patients affected by GM1 and GM2 gangliosidoses and NPC. Azafaros is thankful to the patients and their families for their important contribution to the RAINBOW study. Azafaros is now poised to embark on a global Phase 3 trial next year.”
Lead RAINBOW investigator, Roberto Giugliani, added: “We are pleased to report the completion of this important step in the development of a new therapy for GM2 gangliosidosis and Niemann-Pick disease type C, which delivers data to determine the best dosing of nizubaglustat and allows the planning of the next phase.”
In a statement, a representative from the Associação Niemann-Pick & Batten Brasil (ANPB), a patient organisation in Brazil, said there is an urgent need for new treatments for NPC.
"Current therapeutic options are limited and do not offer a definitive cure. Clinical research plays a crucial role in this process, allowing the development and evaluation of new therapies that can improve patients' quality of life and slow the progression of the disease. Therefore, we are excited about developing innovative and convenient therapies.”
About nizubaglustat
Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC).
Nizubaglustat has received the following designations and support:
United States Food and Drug Administration (FDA)
Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC.
Orphan Drug Designations (ODD) for GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC.
IND Clearance and Fast Track Designation for GM1/GM2 gangliosidoses and NPC
European Medicines Agency (EMA)
Orphan Medicinal Product Designation (OMPD) for the treatment of GM2 gangliosidosis.
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Innovation Passport for the treatment of GM1 and GM2 gangliosidoses.
About GM1 and GM2 Gangliosidoses
GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS), resulting in progressive and severe neurological impairment and early death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.
About Niemann-Pick Disease Type C (NPC)
Niemann-Pick disease type C (NPC) is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood.
About Azafaros
Azafaros is a clinical-stage company founded in 2018 by scientists with a deep understanding of rare genetic disease mechanisms, using discoveries made by scientists at Leiden University and Amsterdam UMC. Azafaros is led by a team of highly experienced industry experts and aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. The Azafaros team is dedicated to rapidly bring new drugs to the rare disease patients who need them. The company is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619007436/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Princess Alexandra Hospital NHS Trust Enhances its Cybersecurity with Armis19.2.2025 09:00:00 CET | Press release
Healthcare delivery organization effectively balances innovation and security to drive improved quality of care Armis, the cyber exposure management & security company, today announced that it is enabling The Princess Alexandra Hospital NHS Trust (PAHT) to protect its entire attack surface and manage cyber risk exposure in real time, underpinning the delivery of world-class patient care. PAHT leverages AI-powered Armis CentrixTM, the Armis Cyber Exposure Management Platform, to proactively identify and mitigate all cyber asset risks, remediate security findings and vulnerabilities and protect the entire attack surface. Armis CentrixTM for Medical Device Security is a specialized solution engineered to protect healthcare institutions from the growing threat landscape targeting medical devices. “Putting quality first is the Trust’s approach to everything we do as we strive for excellence, and cybersecurity is no exception,” said Jeffrey Wood, Deputy Director of ICT at PAHT. “Armis has su
SES Enables Viasat Energy Services’ Asia-Pacific Customer to Experience High-Performance Connectivity19.2.2025 08:50:00 CET | Press release
SES’s O3b mPOWER enhances offshore operations with high-performance connectivity to a Floating Production Storage and Offloading (FPSO) vessel SES announced today that O3b mPOWER, its second-generation medium Earth orbit (MEO) satellite system, was deployed to a Viasat Energy Services’ customer operating an offshore vessel in the Asia-Pacific (APAC) region. This collaboration represents Viasat Energy’s first adoption of MEO satellite technology in APAC and their inaugural implementation of O3b mPOWER services globally. Offshore Energy mPOWERED was deployed in late October 2024 aboard a Floating Production Storage and Offloading Vessel (FPSO), delivering high-performance connectivity tailored to the specific needs of the offshore energy sector. The O3b mPOWER connectivity will support both critical and non-critical communications onboard, ensuring reliable, high-speed connectivity with guaranteed service level agreement (SLA). This deployment marks a significant step forward in enabling
Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)19.2.2025 07:00:00 CET | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications. Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications. In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution. "As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Pe
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars19.2.2025 03:57:00 CET | Press release
Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab) in the EU marketEuropean Commission approval based on totality of evidence including extensive comparative analytical, pharmacokinetic and clinical dataThe company expands its biosimilar portfolio to 11 in 2025 as planned, further strengthening its commitment to a portfolio of 22 drugs by 2030 Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic CNV); and Stoboclo® and Osenvelt® (CT-P41, denosumab), biosimilars ref
IFF Reports Fourth Quarter and Full Year 2024 Results18.2.2025 22:49:00 CET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Management Commentary "IFF delivered a solid performance in 2024, reflecting the hard work and dedication of our global team,” said CEO Erik Fyrwald. "Their commitment to serving our customers with industry-leading innovation drove strong top and bottom-line financial results. I’m pleased with the significant progress we’ve made over the past year yet believe that we still have more work to do to realize IFF's full potential. In 2025, we'll strategically increase our investment in R&D, commercial, capacity and technology as we aim to continue to strengthen IFF. Recognizing ongoing macroeconomic uncertainties, we remain confident in our strategy and our ability to navigate challenges as we continue to create long-term value for all shareholders." Full year 2024 Consolidated Financial Results Reported net sales for the full year were $11.48 billion,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom